EE694 Evaluation of Healthcare Resource Utilization and Cost Among First-Line Patients Receiving Ibrutinib Vs Acalabrutinib for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Commercial Claims Database Analysis
Abstract
Authors
B. Muluneh J. He Z. Ding A. Bokun Z.P. Qureshi